Belatacept + Everolimus
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Delayed Graft Function
Conditions
Delayed Graft Function
Trial Timeline
Apr 1, 2014 → Jan 18, 2019
NCT ID
NCT02134288About Belatacept + Everolimus
Belatacept + Everolimus is a phase 1 stage product being developed by Bristol Myers Squibb for Delayed Graft Function. The current trial status is terminated. This product is registered under clinical trial identifier NCT02134288. Target conditions include Delayed Graft Function.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02134288 | Phase 1 | Terminated |
Competing Products
8 competing products in Delayed Graft Function
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Lemborexant + Placebo | Eisai | Approved | 85 |
| Belatacept + Calcineurin Inhibitor | Bristol Myers Squibb | Phase 2 | 51 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 20 |
| Desflurane + Propofol | Baxter | Approved | 82 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 25 |